http://orcid.org/0000-0001-8905-0220
Citations (17)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Wenhui Zhang, Shitong Xie, Rongfeng Fu, Yunfei Chen, Wei Liu, Ting Sun, Mankai Ju, Huiyuan Li, Feng Xue, Lei Zhang, Xiaofan Liu & Renchi Yang. (2023) Fatigue and health-related quality of life in patients with immune thrombocytopenia: a longitudinal assessment in China. Expert Review of Hematology 0:0, pages 1-9.
Read now
Read now
Melanie Sandvad, Emilie Arntoft Pedersen, Henrik Frederiksen & Nikolaj Mannering. (2021) Risk of infection in adult patients with primary immune thrombocytopenia (ITP): a systematic review. Expert Review of Hematology 14:10, pages 961-974.
Read now
Read now
Barbara Skopec, Zuzana Sninska, Nikolai Tzvetkov, Vladlen Ivanushkin, Katja Björklöf, Jane Hippenmeyer & Georgi Mihaylov. (2021) Effectiveness and safety of romiplostim among patients with newly diagnosed, persistent and chronic ITP in routine clinical practice in central and Eastern Europe: an analysis of the PLATON study. Hematology 26:1, pages 497-502.
Read now
Read now
Maria L. Lozano, Bertrand Godeau, John Grainger, Axel Matzdorff, Francesco Rodeghiero, Jane Hippenmeyer & David J. Kuter. (2020) Romiplostim in adults with newly diagnosed or persistent immune thrombocytopenia. Expert Review of Hematology 13:12, pages 1319-1332.
Read now
Read now
Articles from other publishers (13)
Axel Rüfer & Deirdra R. Terrell. (2023)
Burden of immune thrombocytopenia (
ITP
): Special considerations for refractory
ITP
. British Journal of Haematology 203:1, pages 79-85.
Crossref
Crossref
Nan Shen, Jibing Qiao, Yazhou Jiang, Hanjun Yin, Min Li, Suyue Zhu & Jianqin Li. (2023) Safety of non‑peptide thrombopoietin receptor agonists in patients with immune thrombocytopenia: A systematic review and meta‑analysis of short‑term double‑blind randomized clinical trials. Experimental and Therapeutic Medicine 26:2.
Crossref
Crossref
Azza Abdel Gawad Tantawy, Nayera Hazaa Khalil Elsherif, Fatma Soliman Ebeid, Rasha Abd El-Rahman El-Gamal, Eman Abdel Rahman Ismail, Mahmoud A. Kenny & Michael Botros Elkes morcos. (2022) Evaluation of the effect of eltrombopag therapy on the platelet collagen receptor glycoprotein VI (GPVI) expression and soluble GPVI levels in young patients with immune thrombocytopenia. Journal of Thrombosis and Thrombolysis 55:2, pages 243-251.
Crossref
Crossref
Prantar Chakrabarti, Biju George, Chandrakala Shanmukhaiah, Lalit Mohan Sharma, Shashank Udupi & Waleed Ghanima. (2022) How do patients and physicians perceive immune thrombocytopenia (ITP) as a disease? Results from Indian analysis of ITP World Impact Survey (I-WISh). Journal of Patient-Reported Outcomes 6:1.
Crossref
Crossref
Ruoxi Zhang, Miao Chen, Chen Yang & Bing Han. (2022) Efficacy and steroid-sparing effect of tacrolimus in patients with autoimmune cytopenia. Annals of Hematology 101:11, pages 2421-2431.
Crossref
Crossref
Alicia Rovó, Nathan Cantoni, Kaveh Samii, Axel Rüfer, Giedre Koenen, Sandra Ivic, Davide Cavanna & Rudolf Benz. (2022) Real-world impact of primary immune thrombocytopenia and treatment with thrombopoietin receptor agonists on quality of life based on patient-reported experience: Results from a questionnaire conducted in Switzerland, Austria, and Belgium. PLOS ONE 17:4, pages e0267342.
Crossref
Crossref
Manraj N. Kaur, Donald M. Arnold, Nancy M. HeddleRichard J. CookCyrus HsiaMark BlosteinErin JamulaMichelle SholzbergYulia Lin, Jeannine KassisLoree LarrattAlan Tinmouth, Julie CarruthersNa LiYang LiuFeng Xie. (2022) Cost-effectiveness of eltrombopag vs intravenous immunoglobulin for the perioperative management of immune thrombocytopenia. Blood Advances 6:3, pages 785-792.
Crossref
Crossref
Ricardo Viana, Denise D’Alessio, Laura Grant, Nichola Cooper, Donald Arnold, Mervyn Morgan, Drew Provan, Adam Cuker, Quentin A. Hill, Yoshiaki Tomiyama & Waleed Ghanima. (2021) Psychometric Evaluation of ITP Life Quality Index (ILQI) in a Global Survey of Patients with Immune Thrombocytopenia. Advances in Therapy 38:12, pages 5791-5808.
Crossref
Crossref
Susan D. Mathias. (2020)
I‐WISh
: A wish list for immune thrombocytopenia quality of life indicators becomes reality
. American Journal of Hematology 96:2, pages 172-173.
Crossref
Crossref
Suvir Singh & Komalpreet Kaur. (2021) Initial data on clinical use of generic romiplostim for second-line and subsequent therapy of immune thrombocytopenia in India. Indian Journal of Medical Specialities 12:1, pages 19.
Crossref
Crossref
C. Mettler, A. Daguzan, M.-C. Lagouanelle, A. Briantais, P. Ducros, S. Laborde, S. Gouiran, N. Schleinitz, B. Faucher & M. Ebbo. (2021) Attentes en éducation thérapeutique des patients atteints de purpura thrombopénique immunologique et des soignants. La Revue de Médecine Interne 42:1, pages 3-10.
Crossref
Crossref
Rachael F. Grace, Robert J. Klaassen, Kristin A. Shimano, Michele P. Lambert, Amanda Grimes, James B. Bussel, Vicky R. Breakey, Yves D. Pastore, Vandy Black, Kathleen Overholt, Rukhmi Bhat, Peter W. Forbes & Cindy Neunert. (2020) Fatigue in children and adolescents with immune thrombocytopenia. British Journal of Haematology 191:1, pages 98-106.
Crossref
Crossref
Tadeusz Robak, Maciej KaźmierczakIsidro Jarque, Vasile MusteataJacek TrelińskiNichola CooperPeter KiesslingUte MassowFranz WolteringRose SnipesJuan KeGrant LangdonJames B. Bussel & Stephen Jolles. (2020) Phase 2 multiple-dose study of an FcRn inhibitor, rozanolixizumab, in patients with primary immune thrombocytopenia. Blood Advances 4:17, pages 4136-4146.
Crossref
Crossref